Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Fetal Tracheal Balloon Study in Diaphragmatic Hernia

This study has been terminated.
(Device no longer available)
Information provided by (Responsible Party):
Francois Luks, Rhode Island Hospital Identifier:
First received: August 26, 2009
Last updated: May 4, 2015
Last verified: May 2015
The purpose of this phase 2 limited study is to examine whether prenatal intervention correct the lung underdevelopment associated with severe diaphragmatic hernia.

Condition Intervention Phase
Diaphragmatic Hernia
Lung Disease
Device: Fetal tracheal obstruction with detachable balloon (device)
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2 Fetal Tracheal Balloon (IDE G080077) Study in Diaphragmatic Hernia

Resource links provided by NLM:

Further study details as provided by Rhode Island Hospital:

Primary Outcome Measures:
  • Survival at birth [ Time Frame: Newborn period (1 day) ]

Secondary Outcome Measures:
  • Survival at 30 days [ Time Frame: 30 days ]
  • Maternal complications [ Time Frame: 30 days ]
  • Fetal morbidity [ Time Frame: 30 days ]
  • In utero lung growth (LHR) [ Time Frame: 30 days ]

Enrollment: 3
Study Start Date: September 2008
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Detachable balloon
Fetuses treated with endoscopic tracheal occlusion
Device: Fetal tracheal obstruction with detachable balloon (device)
  • Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.
  • Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation.
Other Name: Goldvalve Balloon, nFocus Neuromedical, Inc.

Detailed Description:

Congenital diaphragmatic hernia (CDH) has traditionally been associated with very high mortality rates. Most infants died of pulmonary hypoplasia and severe pulmonary hypertension. This led to correction of CDH and pulmonary hypoplasia before birth. Unfortunately, maternal morbidity of open fetal surgery was significant and fetal mortality was very high (>60%). Moreover, the results of postnatal therapy for CDH improved dramatically, from less than 20% survival several decades ago to more than 70% today.

Fetal intervention has evolved as well, to a minimally invasive approach that involves a single endoscopic port and occlusion of the fetal trachea. While this has considerably decreased the morbidity and fetal mortality of the in utero procedure, its results do not exceed the overall (i.e., non-stratified) results of contemporary postnatal treatment. Most recently, a multicentric cooperative study under (Eurofoetus) has conducted a clinical trial comparing postnatal treatment with endoscopic fetal tracheal occlusion for the most severe forms of CDH. Results of the Eurofoetus trial and of a recent retrospective review involving European and North-American centers have shown the following: 1) It is possible to identify a specific subgroup of fetuses with CDH in whom survival can be predicted to be less than 10%, despite all current methods of postnatal treatment, 2) Survival of fetuses with predicted postnatal survival of 8% was >50% following endoscopic fetal tracheal occlusion, and 3) Fetal tracheal occlusion in that group resulted in an increase in lung size (LHR), from an average of 0.7 pre-intervention, to 1.7 post-intervention.

Based on the available research literature, the results of the Eurofoetus trial, and this institution's experience with endoscopic fetal surgery, we hypothesize that in the highest risk group of fetuses with congenital diaphragmatic hernia, where chances of survival is estimated at less than 10%, endoscopic fetal tracheal occlusion in late second trimester, with reversal of occlusion in mid-third trimester, allows catch-up lung growth and maturation and converts the condition into one with intermediate to good prognosis (predicted survival 50-60%). We propose to offer this form of treatment, under an FDA-approved Investigational Device Exemption (G080077), to eligible patients, on a case-by-case basis, after discussion before a multidisciplinary board.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Singleton pregnancies
  • Isolated congenital diaphragmatic hernia
  • Normal karyotype (amniocentesis)
  • Initial diagnosis before 26 weeks gestation
  • Competent cervix
  • Severity of CDH: lung-to-head ratio (LHR) ≤0.8 at 22-26 weeks gestation
  • Liver herniation in the chest
  • Informed consent

Exclusion Criteria:

  • Preterm labor, premature rupture of membranes or amniotic leak
  • Significant maternal morbidity
  • Minor (<18 years)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00966823

United States, Rhode Island
Rhode Island Hospital/Women & Infants' Hospital of Rhode Island
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Rhode Island Hospital
Principal Investigator: Francois I Luks, MD, PhD Rhode Island Hospital
  More Information

Additional Information:

Responsible Party: Francois Luks, Francois I. Luks, MD, PhD, Rhode Island Hospital Identifier: NCT00966823     History of Changes
Other Study ID Numbers: G080077
Study First Received: August 26, 2009
Last Updated: May 4, 2015

Keywords provided by Rhode Island Hospital:
Lung development
Lung growth
Tracheal occlusion
Neonatal death

Additional relevant MeSH terms:
Lung Diseases
Hernia, Diaphragmatic
Hernias, Diaphragmatic, Congenital
Pathological Conditions, Anatomical
Respiratory Tract Diseases
Congenital Abnormalities processed this record on April 28, 2017